WednesdayApr 09, 2008 10:58 am

Smoky Market Foods Inc. (SMKY.OB) is "One to Watch"

Smoky Market Foods, Inc. is focused on producing a complete line of fully-cooked Smoke-Baked meat, poultry and fish through an innovative wood-burning oven system. This proprietary, wood-burning oven technology makes it possible to create products that do not contain harmful additives or chemical preservatives, making Smoky Market foods a healthy alternative to the chemical-laden smoked meat, poultry and fish products flooding the market today. Smoky Market Foods, Inc.'s business plan consists of building a national chain of Smoky Market® restaurant-stores and self-contained kiosks. The company's menu of delicious wood-smoked cuisine is made in a large, USDA-inspected processing facility located in…

Continue Reading

WednesdayApr 09, 2008 9:13 am

Small Cap Voice Featured Client: Tecton Corporation (TTNC.OB)

Tecton Corporation (TTNC.OB) is a mineral exploration and development company with a focus on acquiring and developing a high-quality portfolio of uranium properties. The company is based in the United States with a Swiss-Canadian management team and primarily mines uranium and vanadium property interests in the U.S. and Canada. Tecton has three main projects: Wapata Lake, Firefly, and Ace of Spades. The Wapata Lake Project is located in the Athabasca Basin in northern Saskatchewan, which is the world’s largest producer of uranium. The Athabasca Basin is known as the “global hotspot” for high grade unconformity-related uranium deposits and contains more…

Continue Reading

WednesdayApr 09, 2008 8:54 am

OTCPicks Featured Company: Center for Wound Healing, Inc. (CFWH.PK) Announces Investment of $17.5 Million by Bison Equity Partners II, LP.

As a leading operator of comprehensive wound care treatment centers that offer hyperbaric oxygen therapy and other forms of treatment, The Center for Wound Healing, Inc. (OTC: CFWH) recently received a $17.5 million investment by Bison Capital Equity Partners II, LP. The company's stock rose 34.48 percent on Tuesday, although the terms of the agreement have not been disclosed. Douglas Trussler, a partner at Bison Capital commented on the recent investment, "We are extremely impressed with The Center for Wound Healings track record in operating wound care centers of excellence. The Company's legacy of clinical outcomes and the strength of…

Continue Reading

WednesdayApr 09, 2008 8:43 am

Aida Pharmaceuticals Inc. (AIDA.OB) Develops Wide-Spectrum Antibiotic

Aida Pharmaceuticals Inc. (OTC Bulletin Board: AIDA) today announced its recently-acquired research institute, the Jiangsu Institute of Microbiology Co. Ltd, is working toward the development of a new wide-spectrum antibiotic, Wetimicin, in the People’s Republic of China. The company believes Wetimicin will have a larger market volume than its current product, Etimicin Sulphate. Wetimicin is part of the amino-glycoside family of antibiotics, and is being tested for its efficacy in the treatment of inflammation stemming from respiratory infection, urogenital infection, soft skin tissue infection, as well as trauma from operations and more. Wetimicin’s stronger applicability to such a wide range…

Continue Reading

WednesdayApr 09, 2008 8:38 am

Antigenics Inc. (AGEN) Receives Russian Approval of Cancer Vaccine

U.S. based Antigenics (AGEN-NASDAQ) announced on Tuesday that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage in the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch its Oncophage product in Russia sometime in the second half of 2008. Antigenics is a biotechnology company which is developing products to treat cancer, infectious diseases, and autoimmune disorders. Their most advanced-stage product candidate is Oncophage. Oncophage is a personalized therapeutic cancer vaccine which is based on heat shock protein gp96. Antigenics is currently conducting clinical trials for…

Continue Reading

WednesdayApr 09, 2008 8:31 am

StockGuru Blog: NextGen Bioscience (NXGB) – Potential Candidates and Acquisition Pipeline

Wednesday, April 9th, 2008 NexGen’s proprietary anti-cancer candidates include Prostaganin (targeting prostate cancer) and Tetanolic (targeting breast cancer) which have, in preliminary studies, shown to be able to target cancer cells without affecting normal tissue and therefore have potential to be developed into blockbuster drugs. These patented product candidates hold the potential to treat cancer in a way that is effective and safe for the patient. An exciting acquisition pipeline, including in oncology therapeutics, cancer vaccines and anti-bacterial drugs, ensures that the Company is constantly positioned as a leader in the forefront of developments in treating cancer and infectious disease.…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered